Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALERT~~>>-($FDBL)------------>($FDBL)-------->-($FDBL)
EFLN is the Sole Investment-Grade OTC Reporting stock with the Highest Book_Value/Trading_Price Ratio (currently 16 and very soon it will be Over 250)! The New Assets will soon be $520M v.s. the stock is trading at the joke low $0.98M Market Value now...
http://finance.yahoo.com/news/efuel-efn-corp-announces-lease-133000662.html
https://www.otcmarkets.com/stock/EFLN/news/eFUEL-EFN-CORP--Announces-Lease-Purchase-Agreement-With-Liberty-Mines-Group?id=150520&b=y
$TPRFF Gran Colombia Gold Announces 2017 Outlook and Proposals to Improve Capital Structure
http://www.grancolombiagold.com/news-and-investors/press-releases/press-release-details/2017/Gran-Colombia-Gold-Announces-2017-Outlook-and-Proposals-to-Improve-Capital-Structure/default.aspx
$WPWR Well Power Inc. (WPWR) – Focused on Monetizing Huge Untapped Energy Source WPWR
Houston-based energy technologies company Well Power is focused on the application of a valuable new energy technology for the U.S. oil industry. The technology, called Micro Refinery Units (MRU), was developed by ME Resource Corp., a publicly listed Canadian resource company targeting the acquisition, exploration, and development of oil and gas resource properties in Canada and Internationally. ME Resource has granted Well Power the licensing rights to Texas, along with the first right of refusal for the other U.S. states, to this new technology.
The MRU technology is all about the processing of waste natural gas, a byproduct of oil production that usually ends up being wastefully vented, flared, or stranded. Global gas flaring, the burning off of this excess gas, represents not only a huge energy waste, but also an environmental issue. Gas flaring amounts to roughly 150 billion cubic meters each year, resulting in 400 million metric tons of carbon dioxide equivalent greenhouse gas emissions. To get an idea of the significance, and potential, of gas flaring, consider the fact that global gas flaring represents approximately 30% of the total annual gas requirements of the entire European Union.
Well Power’s licensed MRU technology provides a unique way of taking this waste natural gas and converting it into Green FuelTM and clean power, with a solution that is mobile, high-yield, and economical to deploy. The MRU system combines proven commercial technologies together with a proprietary micro-reactor for hydrocarbon processing and catalytic reactions.
Over and above its obvious value in converting a pollution source into clean power and engineered fuels, including no-sulphur diesel and diluents, the MRU solution is flexible, scalable, modular, efficient, and easily custom configured. The proprietary technology is mobile and can be deployed with minimum capital expenditure.
Well Power’s license allows the company to provide the technology with full-service engineering, design, construction, modular fabrication, maintenance, and construction management services to clients in the upstream areas of exploration and production. Well Power can also provide consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.
For additional information on the technology, see a recent write-up in Oil & Gas Network, at http://issuu.com/oilgasnetwork/docs/ogn_june_2015l
$PMCB Wedge Breakout setting up here... bullish in the long term and neutral consolidation at present...bottom bollie is being stretched as the 100/200 crosses for very strong support which will push PMCB into the .30 plus range after it hits the .10 range bottom...Watch for the reverse to the uptrend as the psar comes down to flip to a bullish buy signal.... PMCB
Go $PMCB
Ticker NGCG:
The Ichimoku cloud is a chart used in technical analysis that shows support and resistance, and momentum and trend directions for a security or investment. It is designed to provide relevant information at a glance using moving averages (tenkan-sen and kijun-sen) to show bullish and bearish crossover points.
$UURAF Ucore Rare Metals Inc. #RareEarths , a junior exploration company, engages in the exploration of rare earth elements in Canada and the United States. It primarily holds a 100% interest in the Bokan Mountain/Dotson Ridge property located on Prince of Wales Island, Alaska. The company was formerly known as Ucore Uranium Inc. and changed its name to Ucore Rare Metals Inc. in June 2010. Ucore Rare Metals Inc. is headquartered in Halifax, Canada. http://ucore.com/
$MFST Medifirst Solutions Is Granted 510(k) FDA Clearance MFST
http://www.marketwired.com/press-release/medifirst-solutions-is-granted-510k-fda-clearance-otc-pink-mfst-2142847.htm
$PMCB Technical Analysis....long term "STRONG HOLD" PMCB
1. Resistance 1: $0.17
2. Resistance 2: $0.1986
$INNL Checking in on Penny Stock Innocoll Holdings plc (NASDAQ:INNL)
http://www.duncanindependent.com/checking-in-on-penny-stock-innocoll-holdings-plc-nasdaqinnl/63179/
$SIPC CO-PACKING & PRIVATE LABELING SIPC
http://sippindustries.com/co-packing-private-label-services/
$FDBL Technically oversold PennyLand coming imo! LONG
$TRQ Turquoise Hill Resources Ltd., together with its subsidiaries, operates as a mining company. The company engages in mining copper, gold, and silver. Its principal material mineral resource property is the Oyu Tolgoi copper-gold mine located in the southern Mongolia. The company was formerly known as Ivanhoe Mines Ltd. and changed its name to Turquoise Hill Resources Ltd. in August 2012. The company was founded in 1994 and is headquartered in Vancouver, Canada.
$PMCB Smart Scan Analysis for PMCB is 100% "BUY" PMCB
$TRQ Upgraded Turquoise Hill Resources Raised to Buy From Hold by Canaccord Genuity
$MFST Bollinger Bands has closed above bottom band by 44.5%; Bollinger Bands are 69.3% narrower than normal.The narrow width of the bands suggests low volatility as compared to MFST's normal range. The bands have been in this narrow range for 3 bars. This is often a sign that a market may be about to initiate a new trend.
$PMCB Pharmacyte Biotech Inc (OTCMKTS:PMCB) Keeps Rolling Along
http://oracledispatch.com/2016/12/22/pharmacyte-biotech-inc-otcmktspmcb-keeps-rolling-along/
$FDBL Friendable Inc., Setting up for Success, Mark Zuckerberg is Obsessed with this Technology
Approximately two week ago, Friendable, Inc. (OTC Pink: FDBL) announced that it has received an investment commitment in the amount of $1.615 million. In connection with this investment, Friendable, Inc. completed the acquisition of live streaming video technology, along with a royalty free, perpetual license to integrate and utilize the technology with the Friendable app, from Hang With, Inc.
Twitter (NASDAQ:TWTR), and Facebook (NASDAQ:FB) have recently jumped on the live video bandwagon, and with contracts to stream live NFL games, Bloomberg TV, and the Democratic and Republic conventions one could say they are thriving.
Further Facebook's Mark Zuckerberg has stated that he is "obsessed" with live streaming.
But what is it worth?
Twitter, Inc. quietly purchased Periscope for just under $100 million in early 2015.
As of August 12, 2015, Periscope had only 10 million users and 2 million daily active users.
$PMCB Chart Inspection on Shares of Pharmacyte Biotech Inc. (PMCB)
http://yankeeanalysts.com/2016/12/23/chart-inspection-on-shares-of-pharmacyte-biotech-inc-pmcb/
$PMCB Summary Of The Resistance After Action Today PMCB
A. Resistance 1: $0.1595
B. Resistance 2: $0.1863
$PMCB Ifosfamide in its active form is usually delivered intravenously and then activated in the liver. The process "works", but much of the drug doesn't make it to the pancreas. To deliver a dose big enough to make a dent in a pancreatic tumor, nasty side effects are almost a given. The Cell-in-a-Box approach circumvents this inefficient form of delivery by inserting encapsulated P450-producing cells very near the tumor itself, which means ifosfamide isn't activated until it's at or near the pancreatic tumor, which means the bulk of the drug is delivered where it needs to be delivered. This in turn means less of the drug is necessary to produce a response. Less of a drug means fewer side effects, without giving up efficacy.
$FDBL - .0018 bottom play - Parabolic SAR will flip at .008. imo
$MFST Americanbulls trigger "BUY" today
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=MFST
$PMCB Value Composite Score Update on PharmaCyte Biotech, Inc. (OTCPK:PMCB)
http://eastoverbusinessjournal.com/value-composite-score-update-on-pharmacyte-biotech-inc-otcpkpmcb/34182/
$PMCB Technical Analysis....long term "STRONG HOLD"
1. Resistance 1: $0.0900
2. Resistance2: $0.1051
http://allotcbb.com/quote.php?symbol=pmcb
$PMCB Trading Monitor: Focusing in on Shares of Pharmacyte Biotech Inc. (PMCB)
http://www.microcapwired.com/trading-monitor-focusing-in-on-shares-of-pharmacyte-biotech-inc-pmcb/39911/
$PMCB Technical Buzz on PharmaCyte Biotech, Inc. (OTCPK:PMCB)
http://wslnews.com/technical-buzz-on-pharmacyte-biotech-inc-otcpkpmcb/31920/
$PMCB Average Directional Index Review for Pharmacyte Biotech Inc. (PMCB)
http://yankeeanalysts.com/2016/11/23/average-directional-index-review-for-pharmacyte-biotech-inc-pmcb/
$PMCB Stock Market Club Alert Strong "STAY LONG"
Smart Scan Chart Analysis confirms that a strong uptrend is in place and that the market remains positive longer term. Strong Uptrend with money management stops. A triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
$PMCB Pharmacyte Biotech Inc (OTCMKTS:PMCB) Soars, Opens Floodgates For Catalysts
https://www.insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-soars-opens-floodgates-for-catalysts/118471/
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.0675 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
$PMCB Checking the Piotroski Score on Shares of PharmaCyte Biotech, Inc. (OTCPK:PMCB)
http://wslnews.com/checking-the-piotroski-score-on-shares-of-pharmacyte-biotech-inc-otcpkpmcb/30136/
$PMCB Focus on RSI and CCI Levels: Pharmacyte Biotech Inc. (PMCB)
http://yankeeanalysts.com/2016/11/29/focus-on-rsi-and-cci-levels-pharmacyte-biotech-inc-pmcb/
$PMCB ~ PharmaCyte Biotech, Inc. DD
FDA Grants Orphan Drug Designation to Pharmacyte Biotech for Pancreatic Cancer Treatment
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=457014
PharmaCyte Biotech Obtains Orphan Drug Designation in Europe for Its Pancreatic Cancer Treatment
http://www.ema.europa.eu/ema/index.jsp?
curl=pages/medicines/human/orphans/2009/11/human_orphan_000395.jsp&mid=WC0b01ac058001d12b
$PMCB PharmaCyte Biotech - Diabetes Treatment Program
$PMCB Pharmacyte Biotech Inc (OTCMKTS:PMCB): Upside Potential On A Phase 2 Catalyst
Mid September, Pharmacyte Biotech Inc (OTCMKTS:PMCB) CEO Kenneth L. Waggoner put out a press release addressing to the company’s pancreatic cancer investigation. Well, it was titled as such, but after touching on pancreatic cancer he went on to say he knows that the company’s share price is frustrating for investors, and that even though it looks like there’s very little going on behind the scenes, the company is working hard and fast to get its treatment back into the clinic.
A phase 2 study should have been well under way now, and certain delays have meant this isn’t yet the case. The delays, Waggoner says, are primarily related the the fact that the drug is a biologic and not an NCE. There’s some validity in what he is saying – biologics are more difficult to develop from a manufacturing and storage perspective – but it probably won’t wash with those shareholders that have held stock for the last two or three years waiting for a catalyst.
Anyway, we think that things are finally about to get moving again, and based on the company’s rhetoric, that we could see the initiation of the long awaited phase 2b at some point early next year.
We also really like the science. The company is using what it calls its Cell in a Box technology to go after a number of oncologic indications, of which pancreatic cancer is the primary target. The MOA is simple, but elegant. Currently, a combo treatment of Abraxane and gemcitabine (two SOC chemo agents) is the gold standard in pancreatic cancer. It works to some degree, but has a really severe toxicity profile, and patients are essentially undergoing treatment to get an extra eight weeks of life, each of which they spend in pain and vomiting. It’s the gold standard, but in this space, that doesn’t mean much.
Pharmacyte’s technology is rooted in a type of encapsulated cell that produces a protein that is otherwise produced only in the liver. With traditional chemotherapy, the chemo is introduced systemically, it passes through the liver, and the cell in question activates it. It then carries on through the system to its target (in this instance, the pancreas). Of course, as well as the pancreas, it’s also being washed around other parts of the body, killing healthy cells as it goes.
With Cell in a Box, a physician injects the encapsulated cell into the patient, as close to the cancerous cells (tumor) as possible. They then introduce a chemo agent called ifosfamide systemically, but at one third the dose of a standard treatment. The ifosfamide would normally need to pass through the liver for activation, but instead it travels to the cell capsules, which absorb it, activate it, and pump it back out on location.
So that’s how it works, what do we know about efficacy so far?
Well, from two trials that have been conducted, we know two important things.
One, that it seems to work. In a phase I trial, as compared to gemcitabine (another SOC chemodrugm, with the data points deriving from an old trial), the Cell in a Box ifosfamide combination increased median survival from 28 to 44 weeks, and the percentage of one-year survivors increased from 18% to 36%.
Two, that it isn’t improved with an increased dose. In a phase II trial, patients took a double dose, and efficacy results were weak. Also at the higher dose, the safety profile was poor.
With proof of concept in place, an established maximum tolerable dose and some sound safety data in hand, it can only be the above mentioned manufacturing issues that are holding Pharmacyte back. And it’s not the first company to require a biologic for an expanded trial, so we know the issue will resolve sooner or later.
Which brings us to a final point, cash. The longer the company holds out on initiating the trial, the longer it is going to have to rely on shareholder cash injections to maintain operations. It’s got about $2 million on hand right now, and burns about $1 million every quarter. Even without the added cost of a phase IIb initiation, therefore, cash wouldn’t last too far in to 2017. As such, we’ll almost certainly see a dilutive raise between now and trial initiation.
PMCB ITS READY!!! BBB = Bottom, Bounce and Breakout!
$VGID, $GNPT, $SURE: $.000x with potential~
$GNPT, $MEDT, $SDVI, COBI, $VGID, $SURE, $LUSI: The next $.00x stock!
CBYL: The cheapest Bio-Tech Nasdaq stock and Reverse-Merger very soon! The 52-week high is $4.82 v.s. at the joke low $0.5199 now! The Analyst's rating is "Strong Buy"! The Cheapest Zero-Debt Bio-tech Nasdaq hidden gem! The Cash Value is $1.40! The $1.37 Book Value over the price is the highest among all the same industry peers! Only 26.32M shares Tiny OS and 13.16M shares Tiny float!
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11458969
$MCET Penny Stock Biotech Report 2016-06-15! About OXIS, Multicell,... projects!
!!! 14-page report! PLEASE READ !!! http://fliphtml5.com/nueh/qrhz/basic
IMMEDIATE ALERT: OXIS INTERNATIONAL, INC. SYMBOL: (OXIS)EXCLUSIVE TECHNOLOGYLICENSING & MAJORMARKET POTENTIAL! OXIS has licensed exclusive rights to three Antibody-drug conjugates (ADC) through an agreement made in early 2015 with MultiCell Immunotherapeutics, Inc. (MCIT). MCIT will prepare these ADCs for further evaluation as prospective therapeutics for the treatment of triple-negative breast cancer, as well as multiple myeloma and associated osteolytic bone disease. Though OXIS is still in its infancy compared to industry giants, the potential for acquisitions or even better yet, a real market driver may not be any greater than RIGHT NOW. It doesn’t take long to look at the numbers of industry comps to show a true opportunity could be presenting itself in a BIG WAY: Multiple Myeloma Presenting Multi BILLION Dollar Opportunity?WWW.OXIS.COM
IMMEDIATE ALERT: OXIS INTERNATIONAL, INC. SYMBOL: (OXIS)SEASONED & EXPERIENCEDMANAGEMENT TEAM But no company can expect to go the distance without a sound leadership team at the helm and OXIS has just that! As CEO, Anthony Cataldo is no stranger to emerging biotech and has been credited with taking companies “to the next level”. In fact Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, inc., now known as Lion Biotechnologies, Inc., (LBIO).Mr. Cataldo created the highly successful Lion/Genesis (LBIO)with the inclusion of assets acquired from the National CancerInstitute for the treatment of stage four melanoma. Cataldomanaged to grow LBIO’s market-cap 250x through a simpleprocess: acquiring strong IP, having a strong research team, andattracting the right group of inside ownership to build a REALbiotechnology enterprise.Mr. Cataldo has extensive experiencein the biotechnology sector havingserved as Chairman/CEO of severalbiotech companies including: MultiCellTechnologies, Inc., Calypte BiomedicalCorporation, and Senetek, PLC.WWW.OXIS.COM
$PYHH Technical Analysis: http://www.barchart.com/technicals/stocks/PYHH
***** $CHRO: Going to be a dollar stock in the long run! *****
$SURE, $COBI, $LUSI, $GNPT, $VGID: Super thin...take little to get to mid $.00x range
$CHRO: A tour of the HP Smart Home at the Cupertino Campus
Followers
|
946
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
90702
|
Created
|
01/02/07
|
Type
|
Free
|
Moderator 4Godnwv | |||
Assistants I Like Bottom Fishing Matt_Chart ospreyeye MaxPowerLove$Ihub |
Welcome to Technical Analysts board, this board is open to all Penny AND Big board stocks
Would you like to receive the Monday Morning Memo from the Technical Analysis board??
Each week the board mods compile a list of potential plays for the week. This list is chairmailed to all subscribers before Market open on Monday am.
Click here and enter a valid email address: http://www.investorshub.com/boards/chairmail_sub.asp?board_id=7882
-------------------------------------
If you would like an Annotated chart, feel free to ask, but please 'reply' to a post of one of the mods. It makes it much easier for us to see.
-------------------------------------
The following charts are provided by stockcharts.com
The power of the triangles
Ascending Triangle is When a chart makes higher lows but not higher highs, entrance on the bottom trendline or when the price breaks above the previous flatline of highs. Sell when the stock makes a lower low.
Descending Triangle is When a stock holds its lows but makes lower highs. Buy at support bottom trendline or makes its first higher high and sell when it loses support or makes a lower low.
Symetrical Triangle is When a stock makes lower highs AND higher lows, buy at the bottom trendline or when the stock makes its first breakout with a higher high and sell when it makes a lower low or profits are made.
________________________________________________________________
Chart Posting Formula: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=10684225
________________________________________________________________
PATTERNS
1. Double Top - #msg-38898323
2. Triple Top - #msg-38909205
----------------------------------------------------------------------------------------------------------------
Technical Analysis Chart Lessons
1. Moving Averages #msg-17587817
2. Moving Averages 2 #msg-17587835
3. MACD indicator #msg-17587768
4. Williams %R indicator #msg-17587714
5. RSI indicator #msg-17587680
6. ADX/DMI indicators #msg-17587655
7. Aroon indicator #msg-17587692
8. Finding Resistance #msg-17587755
9. Finding Support #msg-17587741
10. Stock_Analyzers Entry and Exit strategy #msg-17587731
11. What is a cup and handle: #msg-18255652
12. Parabolic SAR #msg-19208309
13. Moving Averages #msg-19208263
14. Bollinger Bands #msg-19208548
15. The ART of SELLING ON THE ASK #msg-20282564
16. Support & Resistance Levels http://investorshub.advfn.com/boards/read_msg.asp?message_id=21996923
17. Drawing Trendlines http://investorshub.advfn.com/boards/read_msg.asp?message_id=21998432
18. Positive Divergences http://investorshub.advfn.com/boards/read_msg.asp?message_id=21992114
19. Trendline Break + 50% Hold http://investorshub.advfn.com/boards/read_msg.asp?message_id=21962845
20. Using Zig-Zag Re-Tracement Lines http://investorshub.advfn.com/boards/read_msg.aspx?message_id=36464457
Lessons on Market Sentiment
Lesson 1 Emotion http://investorshub.advfn.com/boards/read_msg.asp?message_id=21929364
Lesson 2 Crowd Behavior http://investorshub.advfn.com/boards/read_msg.asp?message_id=21929431
Lesson 3 Volume http://investorshub.advfn.com/boards/read_msg.asp?message_id=21929462
--------------------------------------------------------------------------------
Chart tools:
(1) I use http://www.stockcharts.com for charting
(2) For more info on chart formations, see http://www.chartpatterns.com
(3) Chart indicator definitions http://stockcharts.com/education/IndicatorAnalysis/
(4) OTCBB volume gainers http://www.stockhouse.com/mostactives/index.asp?type=mostactives&exchange=OTCBB
(5) OTCBB biggest %gainers http://www.stockhouse.com/mostactives/index.asp?type=winners&exchange=OTCBB
(6) OTCBB biggest decliners http://www.stockhouse.com/mostactives/index.asp?type=losers&exchange=OTCBB
(7) Find out if your stock is on the SHO List http://www.buyins.net/tools/short_list.php?src=1,7,9
(8) Explore Level II here-http://www.hotstockmarket.com/forums/showthread.php?t=14938
(9) For a COMPLETE list of indicator meanings http://www.investopedia.com/categories/technicalanalysis.asp
(10) Top insider trades website: http://www.secform4.com/top-lists.htm
POST S-8 companies board http://www.investorshub.com/boards/board.asp?board_id=1605
TOXIC FILINGS boardhttp://www.investorshub.com/boards/board.asp?board_id=4318
SEC Filings:
http://www.pinksheets.com/index.jsp
http://www.edgar-online.com/
http://www.nasdaq.com/
http://knobias.tenkwizard.com/main.php
Futures:
http://quotes.ino.com/exchanges/futboard/current/
Indices:
http://www.cme.com/dta/del/globex.html
Foreign Exchange:
http://www.cme.com/trading/dta/del/product_list.html?ProductType=cur
Commodities:
http://www.cme.com/trading/dta/del/product_list.html?ProductType=com
Realtime Indices Charts (2) for World Markets:
http://www.wwfn.com/commentary/oscharts.html (note: auto-refreshes every 60 seconds)
http://www.allstocks.com/markets/World_Charts/Asian_Stock_Markets/asian_stock_markets.html (note: auto-refreshes every 5 minutes)
DISCLAIMER:
Opinions expressed on this board are only people’s opinions. I, nor any moderator or assistant of this board is a licensed broker. Trading strategies discussed on this board are often high risk and not suitable everyone.
No one is responsible for your gains or losses in the market except YOU. If you follow stock strategies, charts and or buy and sells signals discussed on this board you may LOSE ALL YOUR MONEY.
Please weigh the strategies discussed here carefully against what you are willing to risk.
Please do your own due diligence before buying or selling ANY SECURITY in the open market, there are no guarantees.
Posts Today
|
0
|
Posts (Total)
|
90702
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |